GMED Outlook Spooks Investors, CYTX Trials Placed On Hold, INCY Gets FDA Date

Albany Molecular Research Inc. (AMRI: Quote), which reported better-than expected Q2 results, has also upped its full year contract revenue guidance, sending the stock up by more than 7 percent.

The company now expects full year contract revenue to range between $275 million and $283 million, up from its prior outlook of $243 million to $253 million.

AMRI closed Tuesday's trading at $20.29, up 7.98%.

Cytori Therapeutics (CYTX: Quote) plummeted in after-hours trading Tuesday following the company's decision to halt its cell therapy heart failure trials.

According to the company, the multi-center, prospective, randomized, double-blind PMA/IDE safety and feasibility (phase I/II) trials investigating adipose-derived stem and regenerative cells in patients who suffer from a severe form of refractory (untreatable) heart failure due to chronic myocardial ischemia, dubbed ATHENA and ATHENA II, were placed on hold based on a safety review of reported cerebrovascular events.

CYTX closed Tuesday's trading at $2.10, down 0.47%. In after-hours, the stock was down 22.38% to $1.63.

Globus Medical Inc. (GMED: Quote) plunged 19 percent in extended trading on Tuesday as investors were disappointed with downward revision of the company's full-year revenue outlook.

The company now expects full year 2014 net sales to be in the range of $460 million to $465 million, down from its prior estimate of $480-$486 million. The non-GAAP earnings per share guidance for 2014 remained unchanged at $0.90 to $0.92.

GMED closed Tuesday's trading at $22.56, up 1.39%. In after-hours, the stock was down 19.02% to $18.27.

Incyte Corp.'s (INCY: Quote) supplemental New Drug Application for Ruxolitinib as a potential treatment for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea has been assigned priority review by FDA.

See the rest here:
GMED Outlook Spooks Investors, CYTX Trials Placed On Hold, INCY Gets FDA Date